City

Belfast (1)

Handeni (1)

Condition

Cardiac Safety (2)

Cardiotoxicity (1)

Malaria (1)

Parasitemia (1)

Pregnancy Malaria (1)

Overall Status

Completed (2)

Sign in for free

Phase

phase 1 (1)

phase 2 (1)

Sponsor

Calithera Biosciences, Inc (1)

London School of Hygiene and Tropical Medicine (1)

Collaborator

Kilimanjaro Christian Medical Centre, Tanzania (1)

National Institute for Medical Research, Tanzania (1)

Intervention

dihydroartemisinin-piperaquine (dha-pqp) (1)

moxifloxicin (1)

sulfadoxine-pyrimethamine (sp) (1)

telaglenastat (1)

telaglenastat placebo (1)

Study Documents

Assessment report: Eurartesim - dihydroartemisinin / piperaquine phosphate EMEA/H/C/1199 (1)

Intervention Type

drug (2)

other (1)

Funder Type

Industry (1)

Other (1)

Study Type

Interventional (2)

cardiac safety

Showing 1 - 2 of 2

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Cardiac Safety Trial in Belfast (telaglenastat, telaglenastat , moxifloxicin)

Completed

Cardiac Safety

telaglenastat
+2 more

Belfast, Ireland, United Kingdom

Celerion

Mar 8, 2021

Malaria, Pregnancy Malaria, Cardiotoxicity Trial in Handeni (sulfadoxine-pyrimethamine (SP), dihydroartemisinin-piperaquine

Completed

Malaria
+4 more

sulfadoxine-pyrimethamine (SP)
dihydroartemisinin-piperaquine (DHA-PQP)

Handeni, Tanga Region, Tanzania

Handeni District Hospital

Feb 1, 2021